Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 7/20 | 0.55 |
| ▸ | CNR2 | P34972 | 5/20 | 0.55 |
| ▸ | PSMB11 | A5LHX3 | 2/20 | 0.50 |
| ▸ | PSMA7 | O14818 | 2/20 | 0.50 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.50 |
| ▸ | PSMA1 | P25786 | 2/20 | 0.50 |
| ▸ | PSMA2 | P25787 | 2/20 | 0.50 |
| ▸ | PSMA3 | P25788 | 2/20 | 0.50 |
| ▸ | PSMA4 | P25789 | 2/20 | 0.50 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.50 |
| ▸ | PSMB9 | P28065 | 2/20 | 0.50 |
| ▸ | PSMA5 | P28066 | 2/20 | 0.50 |
| ▸ | PSMB4 | P28070 | 2/20 | 0.50 |
| ▸ | PSMB6 | P28072 | 2/20 | 0.50 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.50 |
| ▸ | PSMB10 | P40306 | 2/20 | 0.50 |
| ▸ | PSMB3 | P49720 | 2/20 | 0.50 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.50 |
| ▸ | PSMA6 | P60900 | 2/20 | 0.50 |
| ▸ | PSMA8 | Q8TAA3 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18250209 | 0.92 | CNR1 (0.52) | CNR1CNR2PSMB11PSMA7PSMB1 | |
| SCHEMBL21089981 | 0.90 | CNR1 (0.50) | CNR1CNR2PSMB11PSMA7PSMB1 | |
| SCHEMBL30480569 | 0.90 | CNR1 (0.50) | CNR1CNR2PSMB11PSMA7PSMB1 | |
| SCHEMBL19865733 | 0.90 | CNR1 (0.50) | CNR1CNR2PSMB11PSMA7PSMB1 | |
| SCHEMBL19865784 | 0.90 | CNR1 (0.50) | CNR1CNR2PSMB11PSMA7PSMB1 | |
| SCHEMBL17716482 | 0.88 | CNR1 (0.60) | CNR1CNR2PSMB11PSMA7PSMB1 | |
| SCHEMBL25685182 | 0.85 | CNR1 (0.55) | CNR1CNR2PSMB11PSMA7PSMB1 | |
| SCHEMBL25684813 | 0.83 | CNR1 (0.37) | CNR1CNR2ALDH1A1MAPTHPGD | |
| SCHEMBL2678363 | 0.81 | CNR1 (0.74) | CNR1CNR2PSMB11PSMA7PSMB1 | |
| SCHEMBL2678367 | 0.81 | CNR1 (0.74) | CNR1CNR2PSMB11PSMA7PSMB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3481383-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | CELLIX BIO PRIVATE LTD (IN) | 2023-06-14 | — | — | EP | disclosed |
| EP-3481383-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | CELLIX BIO PRIVATE LTD (IN) | 2023-06-14 | — | — | EP | disclosed |
| US-20220162156-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | Cellix Bio Provate Limited (IN) | 2022-05-26 | — | — | US | disclosed |
| US-20220162156-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | Cellix Bio Provate Limited (IN) | 2022-05-26 | — | — | US | disclosed |
| US-11078154-B2 | Compositions and methods for the treatment of irritable bowel syndrome | CELLIX BIO PRIVATE LIMITED (IN) | 2021-08-03 | — | — | US | disclosed |
| US-11078154-B2 | Compositions and methods for the treatment of irritable bowel syndrome | CELLIX BIO PRIVATE LIMITED (IN) | 2021-08-03 | — | — | US | disclosed |
| US-20190177267-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | CELLIX BIO PRIVATE LIMITED (IN) | 2019-06-13 | — | — | US | disclosed |
| US-20190177267-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | CELLIX BIO PRIVATE LIMITED (IN) | 2019-06-13 | — | — | US | disclosed |
| WO-2018029545-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | CELLIX BIO PRIVATE LIMITED (IN) | 2018-02-15 | — | — | WO | disclosed |
| US-9498461-B2 | Compositions and methods for the treatment of inflammatory bowel disease | CELLIX BIO PRIVATE LIMITED (IN) | 2016-11-22 | — | — | US | disclosed |
| US-9498461-B2 | Compositions and methods for the treatment of inflammatory bowel disease | CELLIX BIO PRIVATE LIMITED (IN) | 2016-11-22 | — | — | US | disclosed |
| US-9333187-B1 | Compositions and methods for the treatment of inflammatory bowel disease | CELLIX BIO PRIVATE LIMITED (IN) | 2016-05-10 | — | — | US | disclosed |
| US-9333187-B1 | Compositions and methods for the treatment of inflammatory bowel disease | CELLIX BIO PRIVATE LIMITED (IN) | 2016-05-10 | — | — | US | disclosed |
| US-20160120839-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | CELLIX BIO PRIVATE LIMITED (IN) | 2016-05-05 | — | — | US | disclosed |
| US-20160120838-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | CELLIX BIO PRIVATE LIMITED (IN) | 2016-05-05 | — | — | US | disclosed |
| US-20160120838-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | CELLIX BIO PRIVATE LIMITED (IN) | 2016-05-05 | — | — | US | disclosed |
| US-20160120839-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | CELLIX BIO PRIVATE LIMITED (IN) | 2016-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160120838-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | ALPI, SLC10A2, SI | CNR1 260/4885CNR2 148/4885PSMB11 1299/4885 |
| US-20220162156-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | SI, SLC10A2, F5 | CNR1 1365/4885CNR2 1080/4885PSMB11 3015/4885 |
| US-11078154-B2 | Compositions and methods for the treatment of irritable bowel syndrome | SI, SLC10A2, ALPI | CNR1 568/4885CNR2 620/4885PSMB11 2984/4885 |
| US-20190177267-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | SI, SLC10A2, F5 | CNR1 1365/4885CNR2 1080/4885PSMB11 3015/4885 |
| US-20160120839-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | ALPI, SLC10A2, SI | CNR1 260/4885CNR2 148/4885PSMB11 1299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.